Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry

Table 3 Clinical features and patterns of methotrexate (MTX) use at etanercept (ETN) initiation^a (ETN Initiator Cohort, n = 465)

Characteristic	Combination therapy^b	Step-up therapy^c	ETN proximate switchers^d	ETN remote switchers^e	MTX add-on^f	ETN only	p-value^g
Active^h enthesitis (n = 67), n (%)	13 (19.4)	15 (22.4)	11 (16.4)	6 (9.0)	3 (4.5)	19 (28.4)	0.073
Active sacroiliitis (n = 33), n (%)	4 (12.1)	8 (24.2)	5 (15.2)	2 (6.1)	1 (3.0)	13 (39.4)
Active joint count, n	91	187	56	31	14	78
Median (IQR)	11.0 (4.0, 20.0)	4.0 (2.0, 8.0)	2.0 (1.0, 8.0)	3.0 (1.0, 8.0)	9.0 (4.0, 17.0)	4.0 (1.0, 7.0)	<.001
CHAQⁱ, n	83	146	42	22	11	65
Median (IQR)	0.9 (0.4, 1.5)	0.4 (0.1, 1.0)	0.6 (0.1, 1.1)	0.3 (0.0, 0.6)	0.8 (0.4, 2.0)	0.6 (0.0, 1.0)	<.001
cJADAS 10^j, n	81	145	47	23	8	61
Median (IQR)	19.0 (13.0, 22.0)	11.0 (7.5, 16.0)	10.5 (6.0, 16.0)	11.0 (6.0, 16.0)	18.8 (14.0, 23.0)	11.5 (8.0, 17.0)	<.001
Physician Global, n	89	175	50	29	13	74
Median (IQR)	5.0 (3.5, 7.0)	3.0 (2.0, 5.0)	3.0 (2.0, 4.0)	3.0 (2.0, 4.0)	6.0 (3.0, 7.0)	4.0 (2.0, 6.0)	<.001
Patient Global, n	82	151	49	24	9	69
Median (IQR)	5.0 (2.0, 6.0)	3.0 (1.0, 5.0)	4.0 (1.0, 5.0)	3.0 (1.5, 5.0)	6.0 (4.0, 6.0)	4.0 (2.0, 6.0)	0.022
Pain^k, n	66	123	34	19	8	56
Median (IQR)	5.0 (2.0, 7.0)	3.0 (2.0, 6.0)	4.5 (2.0, 7.0)	4.0 (1.0, 7.0)	6.5 (5.0, 9.0)	4.5 (2.0, 6.0)	0.014

^a Study visit must have been within 30 days prior to or after date of etanercept (ETN) initiation; ^b combination therapy = methotrexate (MTX) started concurrently with ETN; ^c step-up therapy = MTX started > 1 month prior to ETN and continued > 1 month after ETN; ^d proximate switchers = MTX started> 1 month prior to ETN and discontinued within 1 month prior to or after ETN; ^e ETN remote switchers = MTX discontinued > 1 month prior to start of ETN; ^f MTX add-on = MTX started > 1 month after starting ETN; ^gp-values were calculated across all JIA categories using Pearson’s Chi Square or Fisher’s exact tests for categorical variables, and Wilcoxon rank sum, Kruskal-Wallis, or analysis of variance (ANOVA) for continuous variables depending on normality and the number of groups being compared; ^hactive clinically active, ⁱCHAQ Childhood Health Assessment Questionnaire, ^jcJADAS 10 clinical Juvenile Arthritis Disease Activity Score (10 joints); ^k Pain measured on a Likert scale from 0 (no pain) to 10 (worst pain)

ISSN: 1546-0096